Antiviral treatment and prophylaxis of influenza in primary care: German recommendations

Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
Peter WutzlerExpert Group, German Association for the Control of Virus Diseases and Paul-Ehrlich Society of Germany

Abstract

Antiviral drugs are a valuable supplementation to vaccines for the control and prevention of influenza. In Germany, for treating influenza amantadine, oseltamivir and zanamivir are approved. Amantadine and oseltamivir are also licensed for prophylactic use. On behalf of the Paul-Ehrlich-Society of Germany and the German Association for the Control of Virus Diseases, as two independent scientific societies, the first consensus Conference on the Antiviral Treatment and Prophylaxis of Influenza was held in June 2002. Based on the available data of clinical studies an expert group developed the following recommendations for the appropriate clinical use of the antiviral drugs: (1) since oseltamivir (orally administered) and zanamivir (administered by inhalation) have apparently similar clinical efficacy both drugs can be used alternatively for treatment. (2) Amantadine is not an alternative to the neuraminidase (NA) inhibitors because it is not effective against influenza B viruses, it frequently selects resistant virus mutants and it can cause adverse events. (3) When influenza is prevalent in the community patients with the clinical diagnosis of influenza should be treated with neuraminidase inhibitors if the symptoms are lasting ...Continue Reading

References

Feb 1, 1992·Archives of Internal Medicine·J DegelauK B Crossley
Oct 21, 1998·The Journal of Infectious Diseases·L V GubarevaR G Webster
Mar 17, 1999·JAMA : the Journal of the American Medical Association·J A WildeM C Steinhoff
Jul 15, 1999·JAMA : the Journal of the American Medical Association·A S MontoA Crisp
Oct 8, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·B FreundI Miller
Oct 28, 1999·The New England Journal of Medicine·F G HaydenR G Mills
Dec 11, 1999·Vaccine·V DemicheliJ Deeks
Jul 6, 2000·The Journal of Antimicrobial Chemotherapy·T Szucs
Oct 4, 2000·JAMA : the Journal of the American Medical Association·C B BridgesK Fukuda
Nov 4, 2000·The New England Journal of Medicine·F G HaydenUNKNOWN Zanamivir Family Study Group
Nov 23, 2000·Archives of Internal Medicine·A S MontoJ Schweinle
Feb 15, 2001·JAMA : the Journal of the American Medical Association·R WelliverUNKNOWN Oseltamivir Post Exposure Prophylaxis Investigator Group
Feb 27, 2001·The Pediatric Infectious Disease Journal·R J WhitleyP Ward
Jun 29, 2001·Antiviral Research·M ZambonUNKNOWN Global Neuraminidase Inhibitor Susceptibility Network
Sep 14, 2001·Journal of the American Geriatrics Society·P H PetersP Ward
Nov 30, 2002·Medical Microbiology and Immunology·W Lange, M Schöttler
Dec 21, 2002·The Journal of Antimicrobial Chemotherapy·F Y AokiUNKNOWN IMPACT Study Group
Apr 11, 2003·Scandinavian Journal of Infectious Diseases·Ingrid UhnooUNKNOWN Swedish Consensus Group
Jun 26, 2003·The Journal of Infectious Diseases·Kyoko ShiraishiYoshihiro Kawaoka
Sep 27, 2003·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroshi SuzukiIsamu Sato
Dec 4, 2003·Lancet·Karl G NicholsonMaria Zambon
Dec 3, 2003·Postgraduate Medicine
Apr 7, 2004·Mayo Clinic Proceedings·Andrej TrampuzLarry M Baddour

❮ Previous
Next ❯

Citations

Oct 31, 2006·The Pediatric Infectious Disease Journal·Chien-Hui LinTzou-Yien Lin
May 20, 2008·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Iain StephensonManish Pareek
Mar 31, 2005·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·W Lawrence Drew
Apr 20, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T WeitzelB Schweiger
Nov 16, 2005·Journal of the American Medical Directors Association·Arvydas AmbrozaitisPeter Shult
May 28, 2005·Expert Review of Anti-infective Therapy·P M Colman
Dec 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·Pedro Plans
Nov 22, 2014·The Cochrane Database of Systematic Reviews·Márcia G Alves GalvãoAntonio J L Alves da Cunha
Jun 25, 2017·Scientific Reports·Ching-Tai HuangAvijit Dutta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.